Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
Authors
Keywords
-
Journal
LEUKEMIA
Volume 32, Issue 4, Pages 986-995
Publisher
Springer Nature
Online
2018-01-05
DOI
10.1038/leu.2017.331
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014
- (2017) A D'Souza et al. LEUKEMIA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transplantation for Myeloma — Now or Later?
- (2017) Charles A. Schiffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis
- (2016) Emma C. Scott et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
- (2016) N Majithia et al. LEUKEMIA
- Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
- (2015) R. Kuiper et al. BLOOD
- How I treat high-risk myeloma
- (2015) S. Lonial et al. BLOOD
- Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
- (2015) M Mohty et al. BONE MARROW TRANSPLANTATION
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents
- (2014) V H Jimenez-Zepeda et al. BONE MARROW TRANSPLANTATION
- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
- (2014) Murielle Roussel et al. JOURNAL OF CLINICAL ONCOLOGY
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients
- (2014) Philip L McCarthy et al. Expert Review of Hematology
- Multiple Myeloma: Future Directions in Autologous Transplantation and Novel Agents
- (2013) Parameswaran N. Hari et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma
- (2013) Luciano J. Costa et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Salvage Second Hematopoietic Cell Transplantation in Myeloma
- (2013) Laura C. Michaelis et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
- (2013) Joseph R. Mikhael et al. MAYO CLINIC PROCEEDINGS
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of early relapse after auto-SCT for multiple myeloma
- (2008) S Kumar et al. BONE MARROW TRANSPLANTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now